Lactiplantibacillus plantarum Probio87 supplementation improves functional constipation and associated psychological well-being in adults
In a randomized, double-blind, placebo-controlled trial, 104 adults with functional constipation (Rome IV criteria) received either L. plantarum Probio87 or placebo for 8 weeks, with a 4-week follow-up. Probio87 significantly increased weekly complete spontaneous bowel movements at Week 8 and Week 12 compared to placebo, and improved Rome IV symptom scores, constipation-related quality of life, and HAMD-24 domains (anxiety, sleep, retardation). Exploratory gene-expression analysis showed increased BDNF and reduced IL-1β, CD117, CXCR5, IDO1, DBH, and MLNR expression in the probiotic group.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Lactiplantibacillus plantarum Probio87 supplementation improves functional constipation and associated psychological well-being in adults The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 44/100 (low).
The Claim
Lactiplantibacillus plantarum Probio87 supplementation improves functional constipation and associated psychological well-being in adults
This conclusion is most relevant to: Adults (n=104) meeting Rome IV criteria for functional constipation.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Lactiplantibacillus plantarum Probio87 supplementation improves functional constipation and is associated with peripheral gene-expression responses related to inflammation and the gut-brain axis: a randomized, double-blind, placebo-controlled trial. (Frontiers in nutrition, 2026) —
How It Works
The proposed biological pathway:
- ▸Probio87 supplementation modulates gut microbiota composition
- ▸Alters peripheral gene expression related to inflammation (IL-1β downregulation) and neuroendocrine signaling (BDNF upregulation, DBH downregulation)
- ▸Affects gut motility-related genes (MLNR, CD117) and immune regulation (CXCR5, IDO1)
- ▸Results in improved bowel function and psychological well-being
Who Might Benefit
Evidence fit by population:
- ▸Adults (n=104) meeting Rome IV criteria for functional constipation
Recommended Dose
Not specified in abstract (probiotic dose not given)
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Exploratory gene-expression findings are preliminary and causal mechanisms require further validation
- ▸Single-center trial; results may not generalize to broader populations
- ▸No effect size or dose information provided in abstract
Frequently Asked Questions
What is Lactiplantibacillus plantarum Probio87?▼
It is a probiotic strain (Lactiplantibacillus plantarum) used in this study to treat functional constipation.
How long did the probiotic treatment last?▼
The intervention lasted 8 weeks, followed by a 4-week post-intervention follow-up (total 12 weeks).
What were the main benefits of Probio87?▼
It significantly increased weekly complete spontaneous bowel movements and improved constipation-related quality of life and psychological well-being (anxiety, sleep, retardation) compared to placebo.
Are there any safety concerns?▼
No intervention-related adverse events or clinically relevant abnormalities in hematological, hepatic, or renal safety parameters were observed.
References
- 1.Zheng F, Yang Y, Zhan Y, Zhang ZW, Lu G, Xie D, Zhang SM, Mageswary U, Lee YY, Liong MT. “Lactiplantibacillus plantarum Probio87 supplementation improves functional constipation and is associated with peripheral gene-expression responses related to inflammation and the gut-brain axis: a randomized, double-blind, placebo-controlled trial..” Frontiers in nutrition, 2026. PMID: 42540505 DOI: 10.3389/fnut.2026.1876944